Multiple sclerosis (MS) is a chronic disabling disease of the CNS that affects people during early adulthood. Despite several US FDA-approved medications, the treatment options in MS are limited. Many people with MS explore herbal products treatments to help control their MS and treat their symptoms. Surveys suggest that up to 70-80% of people with MS had tried plants products or bioactive compounds of plants for their MS. Patients with MS using herbal products potentially explore a new area for the research. The phyto therapies most frequently used include diet, omega-3 fatty acids and antioxidants. The most promising therapy for the anti-inflammatory and neuroprotective agents in both relapsing and progressive forms of MS were bioactive compounds of plant like flavonoids, vitamin-c, lipoic acid and vitamin D supplementation and others. In future polyphenols, terpenes, alkaloids, anthocyanidine glycosides, plant amines, volatile oils etc. would play a prominent role in the treatment of MS.
INTRODUCTION
Multiple sclerosis (MS) is a chronic autoimmune, inflammatory neurological disease of the central nervous system (CNS) [1, 2] . MS degenerates the myelinated axons in the CNS, damaging the myelin and the axons to varying degrees [3, 4] . Alone in the U.S., around 250,000 to 350,000 people were diagnosed with MS [5] . Genetically, women are 2-fold more prone for MS than men. Demographical data suggests that people of North European descent are at high risk for MS [2, 7] . MS typically presents in adults 20 to 45 years of age. Sparsely it presents in childhood or middle age [7] . Though the etiology appears to be intricate, this immunological, autoimmune disorder appears to be an amalgamation of genetic susceptibility and non-genetic trigger. Ancillary tests such as MRI and CSF (Cerebro Spinal Fluid) examination offers a lucid diagnosis bolstering the clinical evidences [7] .
The patients may be grouped into four major categories:
1. Relapsing-remitting MS: the most common form, affecting about 85% of MS patients. It is marked by flare-ups (relapses or exacerbations) of symptoms followed by periods of remission, when symptoms improve or disappear.
2. Secondary progressive MS: may develop in some patients with relapsing-remitting disease. For many patients, treatment with diseasemodifying agents helps delay such progression. The disease course continues to worsen with or without periods of remission or levelling off of symptom severity (plateaus).
Primary progressive MS: affects approximately
10% of MS patients. Symptoms continue to worsen gradually from the beginning. There are no relapses or remissions, but there may be occasional plateaus. This form of MS is more resistant to the drugs typically used to treat the disease. 4. Progressive-relapsing MS: a rare form, affecting fewer than 5% of patients. It is progressive from the start, with intermittent flare-ups of worsening symptoms along the way. There are no periods of remission. More than 30% of MS patients have moderate-to severe spasticity, mostly in the legs. Initial clinical findings in MS patients are often sensory disturbances, the most common of which are paresthesias (numbness and tingling), dysesthesias (burning and "pins and needles"), diplopia, ataxia, vertigo, and bladder (urinary sphincter) disturbances, optic neuritis, fatigue occurs in 90% of patients, sexual dysfunction.
DISEASE MODIFYING THERAPIES
The primary objective of the existing disease modifying therapies is to subside the recurrent exacerbations. No curative, FDA-approved therapies for MS are currently available. Symptomatic treatments are aimed at maintaining function and improving quality of life [9] . 
FDA-Approved

OFF-LABEL TREATMENT OPTIONS
The following therapeutic agents have not been approved by the FDA for the treatment of MS, but physicians often use them off label for this purpose: azathioprine (Imuran), methotrexate, cyclophosphamide, mycophenolate mofetil (Cell Cept) and cladribine etc.
DRUGS IN DEVELOPMENT
Several agents aimed at treating MS are currently in the research pipeline are: laquinimod, teriflunomide (Aubagio), BG-12 (Dimethyl Fumarate), daclizumab (Zenapax), alemtuzumab, (Campath/Lemtrada), rituximab (Rituxan), ocrelizumab and ibudilast etc. A standard method of treating MS itself is the use of beta interferons, particularly 1b (Betaseron) and 1a (Avonex) [10] . In general, in response to a foreign stimulus, the body makes proteins known as interferons. There are several types of interferons. Beta interferon is used for MS because it seems to calm the immune system (another type of interferon, gamma, tends to stimulate the immune system). As noted in the Etiology chapter, the autoimmune theory of MS suggests that the immune system appears to be overactive. Therefore, using beta interferons that calm the immune system, rather than gamma interferon that stimulates it, makes sense given the assumptions of the autoimmune theory. However, it is equally important to note, however, that, in spite of the approved use of beta interferons, they do not cure MS. Rather; they seem to decrease the relapse rate, increase the time between attacks and decrease the severity of attacks. In addition, their use seems to decrease the amount of damage detected on follow-up MRI scans [10] . Unfortunately, while both types of beta interferons have beneficial uses, they also have severe side effects. The possible side effects include fever, nausea, and skin reaction at the sight of injection. If interferons are used in an attempt to manage the disease process and if side effects occur as a result, specific herbal remedies may be used in an attempt to alleviate them. 
List of the Medicinal Plants
s. Stachys officinalis (Lamiaceae)
Description: It is a perennial grassland herb growing to 30 to 60 cm tall. Its leaves are stalked on upright stems, narrowly oval, with a heart shaped base, with a wrinkled texture and toothed margins. Major chemical constituents: Glycosides, flavonoids, tannins. Mechanism of Action: It calms, nourishes the nervous system. It reduces the impact that stress has on the body and fights nervous exhaustions. Pharmacodynamic uses: Antianxiety, gall stones, heart burn, blood pressure, migraine, neuralgia and prevent sweating.
RESULTS AND DISCUSSION
Treatments for MS are divided into two large categories: those that are intended to control the disease process and those that help to manage symptoms. Pharmacological agents that intend to control the disease process besides human recombinant IFN-β and glatiramer acetate include a monoclonal antibody against α-4 integrin, natalizumab and a chemotherapy agent, mitoxantrone. These therapies reduce the frequency of relapses and new lesion formation in the brain and reduce the risk of increased disability among patients with relapsing MS. However, these therapies are ineffective in progressive forms of MS, only partially effective in relapsing MS, only available in injectable forms, have significant side effects and are very costly. Common symptoms that MS patients suffer from include fatigue, depression, cognitive impairment, spasticity, pain and imbalance. These symptoms can have a significant negative impact on the patient"s quality of life; hence, treatment targeting these is critical. Pharmacologic or rehabilitative treatments can help with these symptoms to a variable extent but care is still not optimal; therefore, the development of more effective and affordable symptomatic therapies remains a critical goal of MS care.
There is a paucity of well-designed clinical trials assessing the benefit of alternative therapies for treating MS. High-use therapies, which include diet, omega 3 FAs and antioxidants, may have potential benefit in MS as they have immunomodulatory and neuroprotective properties when evaluated in animal models, MS patients and in other chronic disease conditions. Diet, omega-3 FAs and antioxidants also appear to have a high safety profile when used at recommended doses. Omega-3 FAs are a family of polyunsaturated FAs (PUFAs) that contain a common carbon-carbon double bond at the third carbon from the terminal methyl end of the molecule. The parent omega-3 FA is linolenic acid. It is an "essential fatty acid" and cannot be synthesized in humans and therefore must be supplied in the diet. Sources high in linolenic acid are plant-based and include flaxseeds and flaxseed oil, soy and soybean oil, and canola oil. Eicosapentanoic acid (EPA) and docosahexanoic acid (DHA) are two omega-3 FAs that are synthesized from linolenic acid through a series of enzymatic steps [45] . While EPA and DHA can be synthesized from linolenic acid in humans, a ratelimiting enzymatic conversation from linolenic acid to EPA and DHA results in a very low conversion rate to EPA and DHA [46] . Unlike plant oils, which contain no EPA and DHA, fish and fish oils contain high levels of EPA and DHA, particularly cold water fish (e.g., salmon and mackerel). DHA can cross the blood-brain barrier and, along with arachidonic acid, is a major component of neuronal cell membranes [47, 48] . EPA can be converted to prostaglandin I 3 and E 3 , thromboxane A 3 and leukotriene B 5 , and therefore has immunomodulatory capacity, acting as an anti-inflammatory agent [45, 49] .
There is mounting scientific data supporting the role of immune-mediated mechanisms in the pathogenesis of MS. T cells, B cells, and macrophages, along with soluble mediators of inflammation, appear to cause demyelination and axonal and neuronal injury in MS. One common pathway of tissue injury in MS is oxidative stress mediated by reactive oxygen species [50] . The notion that oxidative stress-mediated lipid peroxidation of brain tissue contributes to the pathogenesis in MS is emphasized in recent studies. Serum lipid peroxi-dation generation can be estimated by thiobarbituric acid (TBA) reactivity and has been used to assess the oxidative stress levels. Because of the interest in free radical injury in MS, it is not surprising that various antioxidants such as lipoic acid, vitamin C, vitamin E, and flavonoids, among others, are being explored as having a potential role in prevention or treatment of MS which are present in different parts of plants. For an example Gingko attracted the interest of MS researchers because of its potential as a disease modulatory agent as well as a treatment for cognitive dysfunction in MS. How-ever, gingkolide B, which is a specific compound found in gingko biloba extracts that had beneficial effects on EAE, did not have effects on exacerbations in a doubleblind, placebo-controlled trial of MS [51, 52] . Gingko biloba has been studied as a treatment for cognitive dysfunction in MS in two clinical trials.
CONCLUSION
The clinical applications of β-INT still remain in question due to their adverse effects. In the current clinical space of MS, herbals and nutraceuticals could be thoroughly investigated to fill in the lacunae in the treatment of MS.
